Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease

Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Juan-Pablo Casas, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, UCLEB consortium, Christopher O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan
doi: https://doi.org/10.1101/2020.09.07.20189571
Amand F Schmidt
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
bUCL British Heart Foundation Research Accelerator
cDepartment of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amand.schmidt@ucl.ac.uk
Nicholas B Hunt
dDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gordillo-Marañón
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
bUCL British Heart Foundation Research Accelerator
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pimphen Charoen
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
eDepartment of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
fIntegrative Computational BioScience (ICBS) Center, Mahidol University, Bangkok 10400, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fotios Drenos
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
gDepartment of Life Sciences, College of Health, Medicine, and Life Sciences, Brunel University London, Uxbridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan-Pablo Casas
hDepartment of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
iMassachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mika Kivimaki
jDepartment of Epidemiology and Public Health, University College London, London WC1E 6BT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah A Lawlor
kMRC Integrative Epidemiology Unit at the University of Bristol, Bristol BS8 2BN, UK
lPopulation Health, Bristol Medical School, University of Bristol
mBristol NIHR Bristol Biomedical Research Centre, University Hospitals Bristol National Health Service Foundation Trust and University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Giambartolomei
nIstituto Italiano di Tecnologia, Central RNA Lab, Genova, Italy
oDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olia Papacosta
pPrimary Care and Population Health, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nishi Chaturvedi
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua C Bis
qCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher O’Donnell
rDepartment of Medicine, VA Boston Healthcare System, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goya Wannamethee
pPrimary Care and Population Health, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Wong
sMRC Unit for Lifelong Health and Ageing, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackie F Price
tUsher Institute, University of Edinburgh, EH8 9AG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alun D Hughes
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
sMRC Unit for Lifelong Health and Ageing, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom R Gaunt
kMRC Integrative Epidemiology Unit at the University of Bristol, Bristol BS8 2BN, UK
lPopulation Health, Bristol Medical School, University of Bristol
mBristol NIHR Bristol Biomedical Research Centre, University Hospitals Bristol National Health Service Foundation Trust and University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nora Franceschini
uDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27516
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis O Mook-Kanamori
vDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Zwierzyna
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
bUCL British Heart Foundation Research Accelerator
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reecha Sofat
wInstitute of Health Informatics, University College London, London WC1 E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aroon D Hingorani
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
bUCL British Heart Foundation Research Accelerator
xHealth Data Research UK, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Finan
aInstitute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, United Kingdom
bUCL British Heart Foundation Research Accelerator
cDepartment of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Drug development of cholesteryl ester transfer protein (CETP) inhibition to prevent coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and Mendelian randomization (MR) results. Findings from meta-analyses of CETP inhibitor trials (≥ 24 weeks follow-up) were used to judge between-compound heterogeneity in treatment effects. Genetic data were extracted on 190+ pharmacologically relevant outcomes; spanning 480,698-21,770 samples and 74,124-4,373 events. Drug target MR of protein concentration was used to determine the on-target effects of CETP inhibition and compared to that of PCSK9 modulation. Fifteen eligible CETP inhibitor trials of four compounds were identified, enrolling 79,961 participants. There was a high degree of heterogeneity in effects on lipids, lipoproteins, blood pressure, and clinical events. For example, dalcetrapib and evacetrapib showed a neutral effect, torcetrapib increased, and anacetrapib decreased cardiovascular disease (CVD); heterogeneity p-value < 0.001. In drug target MR analysis, lower CETP concentration (per μg/ml) was associated with CHD (odds ratio 0.95; 95%CI 0.91; 0.99), heart failure (0.95; 95%CI 0.92; 0.99), chronic kidney disease (0.94 95%CI 0.91; 0.98), and age-related macular degeneration (1.69; 95%CI 1.44; 1.99). Lower PCSK9 concentration was associated with a lower risk of CHD, heart failure, atrial fibrillation and stroke, and increased risk of Alzheimer’s disease and asthma. In conclusion, previous failures of CETP inhibitors are likely compound related. CETP inhibition is expected to reduce risk of CHD, heart failure, and kidney disease, but potentially increase risk of age-related macular disease.

Competing Interest Statement

AFS has received Servier funding for unrelated work. MZ conducted this research as an employee of BenevolentAI. Since completing the work MZ is now a full-time employee of GlaxoSmithKline. None of the remaining authors have a competing interest to declare. DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to this paper. TRG receives funding from GlaxoSmithKline and Biogen

Funding Statement

AFS is supported by BHF grant PG/18/5033837 and the UCL BHF Research Accelerator AA/18/6/34223. CF and AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. MGM is supported by a BHF Fellowship FS/17/70/33482. ADH is an NIHR Senior Investigator. We further acknowledge support from the Rosetrees and Stoneygate Trust. The UCLEB Consortium is supported by a British Heart Foundation Programme Grant (RG/10/12/28456). TRG receives support from the UK Medical Research Council (MC_UU_00011/4). DOMK is supported by the Dutch Science Organization (ZonMW-VENI Grant 916.14.023). Alun DH receives support from the UK Medical Research (MC_UU_12019/1). MK is supported by the UK Medical Research Council (MR/S011676/1, MR/R024227/1), National Institute on Aging (NIH), US (R01AG062553) and the Academy of Finland (311492). DAL is supported by a Bristol BHF Accelerator Award (AA/18/7/34219), and works in a unit that recieves support from the University of Bristol and the UK Medical Research Council (MC_UU_00011/6). DAL is a National Institute of Health Research Senior Investigator (NF-0616-10102).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Analyses were based on aggregated data, which received ethical approval at the source, and as such did not require further ethical approval

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Changed the title

Data Availability

All data are publicly available, as described in the methods section. Please contact AFS for access to specific files, data, or analysis scripts.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 16, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease
Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Juan-Pablo Casas, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, UCLEB consortium, Christopher O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan
medRxiv 2020.09.07.20189571; doi: https://doi.org/10.1101/2020.09.07.20189571
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease
Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Juan-Pablo Casas, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, UCLEB consortium, Christopher O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan
medRxiv 2020.09.07.20189571; doi: https://doi.org/10.1101/2020.09.07.20189571

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)